GlassScriptPhysician profile
Robert J Casquejo
NPI 1043317050
$473,665.69
in general payments reported to CMS, 2019-2025
33 companies · $103K in 2025
The $103K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37K · 2022: $89K · 2023: $124K · 2024: $120K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $180K · Travel and Lodging: $79K · Consulting Fee: $53K · Food and Beverage: $29K · Debt Forgiveness: $5,270 · Education: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $180,283.50 |
| Travel and Lodging | $78,769.69 |
| Consulting Fee | $53,206.50 |
| Food and Beverage | $28,989.83 |
| Debt Forgiveness | $5,270.00 |
| Education | $462.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $148,525.78 | 2021-2025 | Otezla, Otezla, Enbrel |
| Abbvie INC. | $75,061.44 | 2021-2025 | |
| Lilly USA, LLC | $69,890.20 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $55,108.69 | 2023-2025 | Zoryve |
| Incyte Corporation | $40,171.29 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $28,396.85 | 2021-2025 | Sotyktu |
| Ucb, INC. | $13,527.35 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $8,161.95 | 2021-2025 | Jublia, Siliq, Targretin |
| Novartis Pharmaceuticals Corporation | $7,038.47 | 2021-2025 | |
| Eli Lilly and Company | $5,716.57 | 2024-2025 | Ebglyss |
| Leo Pharma INC. | $5,568.68 | 2021-2025 | Adbry, Anzupgo |
| Acera Surgical, INC. | $5,270.00 | 2023 | Restrata Wound Matrix |
| Sun Pharmaceutical Industries INC. | $3,241.29 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $1,801.13 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Dermavant Sciences, INC. | $1,248.88 | 2022-2024 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $988.17 | 2021-2025 | |
| Almirall LLC | $687.31 | 2021-2025 | Klisyri, Seysara |
| Janssen Scientific Affairs, LLC | $634.79 | 2022-2025 | Tremfya |
| Galderma Laboratories, L.P. | $624.65 | 2021-2025 | Nemluvio, Aklief |
| Medimetriks Pharmaceuticals, INC. | $523.69 | 2022-2024 | Clindacin Etz, Neo-Synalar |
| Genzyme Corporation | $449.58 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $290.85 | 2021-2025 | Dupixent |
| Botanix Sb INC | $227.01 | 2025 | Sofdra |
| Journey Medical Corporation | $137.46 | 2022-2024 | |
| Pharming Healthcare, INC. | $125.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.13 | 2022-2023 | Spevigo |
| Epi Health, LLC | $44.88 | 2021 | |
| Hill Dermaceuticals, INC. | $43.09 | 2025 | Tolak |
| Kerecis Limited | $31.12 | 2021 | |
| Biofrontera INC. | $19.69 | 2021 | |
| Strata Skin Sciences, INC. | $19.44 | 2025 | Xtrac |
| Organon LLC | $17.14 | 2025 | Vtama |
| Fidia Pharma USA INC. | $16.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Casquejo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.